181 related articles for article (PubMed ID: 38002324)
1. Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy.
Mafla-España MA; Torregrosa MD; Beamud-Cortés M; Bermell-Marco L; Rubio-Briones J; Cauli O
Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002324
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Frailty Criteria, Cognitive Function, Depressive and Insomnia Symptoms in Men with Localized and Advanced Prostate Cancer under Androgen Deprivation Therapy.
Mafla-España MA; Torregrosa MD; Beamud-Cortés M; Bermell-Marco L; Rubio-Briones J; Cauli O
Healthcare (Basel); 2023 Apr; 11(9):. PubMed ID: 37174808
[TBL] [Abstract][Full Text] [Related]
3. Frailty syndrome is associated with changes in peripheral inflammatory markers in prostate cancer patients undergoing androgen deprivation therapy.
Navarro-Martínez R; Serrano-Carrascosa M; Buigues C; Fernández-Garrido J; Sánchez-Martínez V; Castelló-Domenech AB; García-Villodre L; Wong-Gutiérrez A; Rubio-Briones J; Cauli O
Urol Oncol; 2019 Dec; 37(12):976-987. PubMed ID: 31521528
[TBL] [Abstract][Full Text] [Related]
4. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
5. Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level.
Rouleau M; Neveu B; Caron P; Morin F; Toren P; Lacombe L; Turcotte V; Lévesque É; Guillemette C; Pouliot F
J Urol; 2022 Dec; 208(6):1214-1225. PubMed ID: 36102111
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
[TBL] [Abstract][Full Text] [Related]
7. Deficiency in androgens and upregulation of insulin-like growth factor-1 are involved in high bone turnover in men receiving androgen deprivation therapy for prostate cancer.
Ishizaki F; Hara N; Takizawa I; Nishiyama T; Isahaya E; Kawasaki T; Takahashi K
Growth Horm IGF Res; 2012; 22(3-4):122-8. PubMed ID: 22579549
[TBL] [Abstract][Full Text] [Related]
8. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
[TBL] [Abstract][Full Text] [Related]
9. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.
Takizawa I; Nishiyama T; Hara N; Isahaya E; Hoshii T; Takahashi K
Prostate; 2010 Sep; 70(13):1395-401. PubMed ID: 20687212
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
Bélanger A; Dupont A; Labrie F
J Clin Endocrinol Metab; 1984 Sep; 59(3):422-6. PubMed ID: 6086697
[TBL] [Abstract][Full Text] [Related]
11. Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel.
Ryan CJ; Dutta S; Kelly WK; Middleberg R; Russell C; Morris MJ; Taplin ME; Halabi S;
Clin Genitourin Cancer; 2020 Jun; 18(3):222-229.e2. PubMed ID: 32273234
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Brain Functions in Men with Prostate Cancer under Androgen Deprivation Therapy: A One-Year Longitudinal Study.
Sánchez-Martínez V; Buigues C; Navarro-Martínez R; García-Villodre L; Jeghalef N; Serrano-Carrascosa M; Rubio-Briones J; Cauli O
Life (Basel); 2021 Mar; 11(3):. PubMed ID: 33802213
[TBL] [Abstract][Full Text] [Related]
13. Novel dehydroepiandrosterone troche supplementation improves the serum androgen profile of women undergoing in vitro fertilization.
Keane KN; Hinchliffe PM; Namdar N; Conceicao JL; Newsholme P; Yovich JL
Drug Des Devel Ther; 2015; 9():5569-78. PubMed ID: 26487801
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate.
Labrie C; Simard J; Zhao HF; Belanger A; Pelletier G; Labrie F
Endocrinology; 1989 Jun; 124(6):2745-54. PubMed ID: 2524377
[TBL] [Abstract][Full Text] [Related]
15. Osteoblasts Generate Testosterone From DHEA and Activate Androgen Signaling in Prostate Cancer Cells.
Moon HH; Clines KL; O'Day PJ; Al-Barghouthi BM; Farber EA; Farber CR; Auchus RJ; Clines GA
J Bone Miner Res; 2021 Aug; 36(8):1566-1579. PubMed ID: 33900658
[TBL] [Abstract][Full Text] [Related]
16. Effect of castration monotherapy on the levels of adrenal androgens in cancerous prostatic tissues.
Arai S; Miyashiro Y; Shibata Y; Tomaru Y; Kobayashi M; Honma S; Suzuki K
Steroids; 2011 Feb; 76(3):301-8. PubMed ID: 21147140
[TBL] [Abstract][Full Text] [Related]
17. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer.
Cheung AS; Hoermann R; Dupuis P; Joon DL; Zajac JD; Grossmann M
Eur J Endocrinol; 2016 Sep; 175(3):229-37. PubMed ID: 27340081
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy of different androgens measured by LC-MS/MS in representing hyperandrogenemia and an evaluation of adrenal-origin androgens with a dexamethasone suppression test in patients with PCOS.
Chen F; Chen M; Zhang W; Yin H; Chen G; Huang Q; Yang X; Chen L; Lin C; Yin G
J Ovarian Res; 2021 Feb; 14(1):32. PubMed ID: 33583431
[TBL] [Abstract][Full Text] [Related]
19. Falls and Frailty in Prostate Cancer Survivors: Current, Past, and Never Users of Androgen Deprivation Therapy.
Winters-Stone KM; Moe E; Graff JN; Dieckmann NF; Stoyles S; Borsch C; Alumkal JJ; Amling CL; Beer TM
J Am Geriatr Soc; 2017 Jul; 65(7):1414-1419. PubMed ID: 28263373
[TBL] [Abstract][Full Text] [Related]
20. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
